Marc Tessier-Lavigne
CIK 1437435 · EVP, RESEARCH DRUG DISCOVERY · last filed 2025-06-05
Marc Tessier-Lavigne is an EVP, RESEARCH DRUG DISCOVERY who has filed 63 SEC Form 4 insider transactions across 6 companies since 2008. The most recent filing, for DNLI, was dated Jun 5, 2025. Across all open-market trades the lifetime net is −$93.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $49.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$49.23M
6
63
-$93.00M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DNLI | Director | 1,965,424 | $24.16 | $47.48M | -$36.87M | 25 | 2025-06-05 |
| REGN | Director | 2,434 | $717.93 | $1.75M | -$54.63M | 25 | 2023-01-05 |
| AGIO | Director | — | $32.89 | — | $0 | 3 | 2016-06-23 |
| Juno Therapeutics, Inc. (JUNO) Delisted | Director | 250,000 | — | — | $0 | 3 | 2016-06-21 |
| PFE | Director | — | $24.85 | — | $0 | 4 | 2015-04-24 |
| DNA | EVP, RESEARCH DRUG DISCOVERY | 29 | $7.96 | $231 | -$1.50M | 1 | 2008-07-18 |
Recent Filings
63 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-05 | DNLI | Grant (A) | +6,037 | $0 | EDGAR |
| 2024-06-04 | DNLI | Grant (A) | +5,967 | $0 | EDGAR |
| 2023-10-03 | REGN | Notice (144) | −16,362 | -$13.18M | EDGAR |
| 2023-06-05 | DNLI | Grant (A) | +4,216 | $0 | EDGAR |
| 2023-01-05 | REGN | Grant (A) | +165 | $0 | EDGAR |
| 2023-01-05 | REGN | Grant (A) | +165 | $0 | EDGAR |
| 2022-11-28 | DNLI | Sell (S) | −20,000 | -$609.6K | EDGAR |
| 2022-11-03 | DNLI | Sell (S) | −20,000 | -$605.5K | EDGAR |
| 2022-10-03 | REGN | Mixed | — | -$3.13M | EDGAR |
| 2022-09-30 | DNLI | Sell (S) | −20,000 | -$616.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.